Cor Medix Inc. CRMD
We take great care to ensure that the data presented and summarized in this overview for CorMedix Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRMD
View all-
Black Rock Inc. New York, NY3.49MShares$17.9 Million0.0% of portfolio
-
Nomura Holdings Inc Tokyo, M02.95MShares$15.1 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.93MShares$15 Million0.0% of portfolio
-
Paul Singer Elliott Investment Management L.P. | West Palm Beach, Fl1.55MShares$7.94 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA1.18MShares$6.06 Million0.0% of portfolio
-
State Street Corp Boston, MA1.11MShares$5.68 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL459KShares$2.35 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny239KShares$1.22 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA206KShares$1.05 Million0.0% of portfolio
-
Morgan Stanley New York, NY196KShares$1 Million0.0% of portfolio
Latest Institutional Activity in CRMD
Top Purchases
Top Sells
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Insider Transactions at CRMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 10
2024
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,982
-7.65%
|
$134,910
$5.17 P/Share
|
|
Mar 13
2024
|
Joseph Todisco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
13,561
+3.7%
|
$40,683
$3.74 P/Share
|
|
Jan 12
2024
|
Erin Mistry Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,389
-7.99%
|
$13,167
$3.47 P/Share
|
|
Jan 12
2024
|
Erin Mistry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+47.66%
|
-
|
|
Jan 12
2024
|
Matthew T David Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,216
-9.81%
|
$15,648
$3.47 P/Share
|
|
Jan 12
2024
|
Matthew T David Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+48.47%
|
-
|
|
Jan 12
2024
|
Elizabeth Masson Hurlburt EVP, Head of Clinical Ops. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,603
-7.94%
|
$13,809
$3.47 P/Share
|
|
Jan 12
2024
|
Elizabeth Masson Hurlburt EVP, Head of Clinical Ops. |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+46.3%
|
-
|
|
Jan 12
2024
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,781
-3.9%
|
$41,343
$3.47 P/Share
|
|
Jan 12
2024
|
Joseph Todisco Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
133,333
+27.41%
|
-
|
|
Dec 15
2023
|
Alan W Dunton |
BUY
Open market or private purchase
|
Direct |
3,000
+16.44%
|
$9,000
$3.3 P/Share
|
|
Dec 14
2023
|
Alan W Dunton |
BUY
Open market or private purchase
|
Direct |
3,000
+19.67%
|
$9,000
$3.45 P/Share
|
|
Dec 12
2023
|
Kaufman Beth Zelnick Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Nov 17
2023
|
Erin Mistry Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+16.95%
|
$4,000
$4.0 P/Share
|
|
Nov 16
2023
|
Steven W Lefkowitz |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+16.58%
|
$30,000
$2.25 P/Share
|
|
Sep 08
2023
|
Joseph Todisco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+4.35%
|
$30,000
$3.71 P/Share
|
|
May 18
2023
|
Myron Kaplan |
BUY
Open market or private purchase
|
Direct |
6,000
+3.49%
|
$24,000
$4.54 P/Share
|
|
May 17
2023
|
Paulo F Costa |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
$40,000
$4.65 P/Share
|
|
May 17
2023
|
Alan W Dunton |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+24.49%
|
$12,000
$4.33 P/Share
|
|
May 17
2023
|
Joseph Todisco Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+2.33%
|
$20,000
$4.58 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 30.6K shares |
|---|---|
| Grant, award, or other acquisition | 333K shares |
| Exercise of conversion of derivative security | 15K shares |
| Payment of exercise price or tax liability | 55K shares |
|---|